1-5 of 5
Marianne de Borja
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial

Jennifer R. Brown, John F. Seymour, Wojciech Jurczak, Andrew Aw, Malgorzata Wach, Arpad Illes, Alessandra Tedeschi, Carolyn Owen, Alan P Skarbnik, Daniel Lysak, Ki-Seong Eom, Martin Šimkovič, Miguel Arturo Pavlovsky, Arnon P. Kater, Barbara F. Eichhorst, Kara Miller, Veerendra Munugalavadla, Ting Yu, Marianne de Borja, Paolo Ghia
Journal: Blood
Blood (2024) 144 (Supplement 1): 1009.
https://doi.org/10.1182/blood-2024-200701
Published: 2024
Journal Articles

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

Clinical Trials & Observations
John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O’Brien, Jennifer R. Brown, Talha Munir, Anthony Mato, Stephan Stilgenbauer, Naghmana Bajwa, Paulo Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach
Journal: Blood
Blood (2023) 142 (8): 687–699.
https://doi.org/10.1182/blood.2022018818
Published: 2023
Includes: Supplemental data
Journal Articles

Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

Richard R. Furman, William G. Wierda, Anna Schuh, Piers EM Patten, Jorge M. Chaves, Jennifer R. Brown, Talha Munir, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, Krish Patel, Jennifer A. Woyach, Anna Butturini, Marianne de Borja, Min Hui Wang, Susan O'Brien, John C. Byrd
Journal: Blood
Blood (2022) 140 (Supplement 1): 9873–9875.
https://doi.org/10.1182/blood-2022-162394
Published: 2022
Journal Articles

Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

John F. Seymour, John C. Byrd, Talha Munir, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O'Brien, Jennifer R. Brown, Anthony R. Mato, Stephan Stilgenbauer, Thomas Fehn, Paulo Andre P. de Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach
Journal: Blood
Blood (2022) 140 (Supplement 1): 7050–7052.
https://doi.org/10.1182/blood-2022-157060
Published: 2022
Journal Articles

Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up

John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O'Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Piers EM Patten, Talha Munir, Krish Patel, Anna Butturini, Marianne de Borja, Min Hui Wang, Nitin Jain, William G. Wierda
Journal: Blood
Blood (2022) 140 (Supplement 1): 9865–9867.
https://doi.org/10.1182/blood-2022-159542
Published: 2022